Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An,

Slides:



Advertisements
Similar presentations
CN-1 Neuropathology of Parkinson’s Disease Dementia James B. Leverenz, MD Associate Professor Neurology and Psychiatry and Behavioral Sciences University.
Advertisements

Dementia with Lewy Bodies
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
The Dementias Dr Giles Richards Consultant Psychiatrist CFT.
Brain Atrophy in Type 2 Diabetes Regional distribution and influence on cognition Featured Article: Chris Moran, M.B., B.C.H., Thanh G. Phan, P.H.D., Jian.
Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
CPC #7: Pathology Barbara J. Crain, MD, PhD February 25, 2009.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
This is an umbrella term, not a disease in its own right. It is a term used for a large group of symptoms that adversely affect the brain and can be caused.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Absence of β-Amyloid Deposits After Immunization in.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: In Vivo Fibrillar β-Amyloid Detected Using [11C]PiB.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Copyright © 1999 American Medical Association. All rights reserved.
Fig. 1 The effects of modelling global volume for the analysis of PDD relative to controls. Atrophy in PDD shown (A) compensated for differences in head.
DOI: /j.neurobiolaging
Diffusion tensor imaging and Tract-Based Spatial Statistics in Alzheimer's disease and mild cognitive impairment  Yawu Liu, Gabriela Spulber, Kimmo K.
Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A
Copyright © 2004 American Medical Association. All rights reserved.
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease  Valérie.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Aging.
The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: A longitudinal case report  Carolin A.M. Koriath,
65 year-old female with Alzheimer’s disease
Alzheimer Disease Mayo Clinic Proceedings
Keith A. Josephs, MD, MST, MSc  Mayo Clinic Proceedings 
Chronic Traumatic Encephalopathy
Statistical parametric mapping for analyzing interictal magnetoencephalography in patients with left frontal lobe epilepsy  Haitao Zhu, Jinlong Zhu, Forrest.
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Volume 10, Issue 3, Pages (January 2015)
CEREBRUM Dr. Jamila EL Medany.
Probing the Biology of Alzheimer's Disease in Mice
A Network Diffusion Model of Disease Progression in Dementia
Pathways to Primary Neurodegenerative Disease
Volume 15, Issue 13, Pages (December 2016)
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
PET Imaging of Tau Deposition in the Aging Human Brain
Volume 77, Issue 2, Pages (January 2013)
Disruption of Large-Scale Brain Systems in Advanced Aging
Network hubs in the human brain
Neurobiological Basis of Language Learning Difficulties
Michel Goedert, Florence Clavaguera, Markus Tolnay 
Neural Correlates of Visual Working Memory
Biomarker Modeling of Alzheimer’s Disease
Figure 1 3D heat maps generated by GBM
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Distributed Neural Systems for the Generation of Visual Images
Brain Imaging: Decoding Your Memories
In vivo tau imaging: Obstacles and progress
Neuroplasticity Failure in Alzheimer's Disease
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Josef Parvizi, Anthony D. Wagner  Neuron 
Orienting Attention Based on Long-Term Memory Experience
Volume 24, Issue 1, Pages (July 2018)
Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology  Rebecca G. Smith,
Interaction between the Amygdala and the Medial Temporal Lobe Memory System Predicts Better Memory for Emotional Events  Florin Dolcos, Kevin S LaBar,
R.A. Armstrong, P.L. Lantos, N.J. Cairns  Pathophysiology 
[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.
CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease  Fang Huang, Minghui Wang, Rong Liu, Jian-Zhi Wang, Eric Schadt, Vahram.
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease 
Tract-specific white matter hyperintensities disrupt neural network function in Alzheimer's disease  Alexander N.W. Taylor, Lana Kambeitz-Ilankovic, Benno.
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody 
Presentation transcript:

Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An, Yusuke Kageyama, Collin English, Gay L. Rudow, Olga Pletnikova, Madhav Thambisetty, Richard O'Brien, Abhay R. Moghekar, Marilyn S. Albert, Peter V. Rabins, Susan M. Resnick, Juan C. Troncoso  Alzheimer's & Dementia: The Journal of the Alzheimer's Association  Volume 15, Issue 1, Pages 8-16 (January 2019) DOI: 10.1016/j.jalz.2018.07.215 Copyright © 2018 Terms and Conditions

Fig. 1 Histopathologic features of primary age-related tauopathy (PART). Low-power digitized scanning view micrograph of Hirano Silver–stained hippocampus of 102-year-old female with definite PART (image scanned at 100X) (A). Semiquantitative categorical scoring of neurofibrillary tangle (NFT) densities on PHF–1 immunohistochemistry and Hirano silver, 200× showing sparse (B), moderate (C), and frequent (D) NFTs. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2019 15, 8-16DOI: (10.1016/j.jalz.2018.07.215) Copyright © 2018 Terms and Conditions

Fig. 2 Comparison of primary age-related tauopathy (PART) and Alzheimer's disease (AD) pathology and associated neurodegenerative features. Heatmaps showing the semiquantitative densities and distribution of neurofibrillary tangle (NFT) in 42 PART subjects (A—left [blue]) and 62 AD subjects (B—left [Red]). Each row represents a subject with PART or AD. Columns represent brain regions. The densities of NFT, that is, 0: none, 1: sparse, 2: moderate, 3: frequent, are color-coded according to the scales depicted in A-below and B-below. The Braak score, presence of associated Lewy body disease (yellow), and TDP-43 proteinopathy (green) in PART and AD are shown on A-right and B-right, respectively. Clinical dementia rating score (CDR) and Clinical dementia rating score sum of boxes (CDR-SB) and tau haplotypes (TAU) are shown in PART with vascular lesions sufficient to cause or contribute to cognitive impairment (red) or without (white) (A). The CERAD A, B, and C grouping of the AD cases corresponds to sparse, moderate, or frequent neuritic plaques [16] (white = none; X = not examined). Abbreviations: ERC, entorhinal cortex; HIPPO, hippocampus; AMY, amygdala, SMTG, superior and middle temporal gyri, IP, inferior parietal lobule; MFG, middle frontal gyrus; OCC, visual cortex (Brodmann's areas 17 and 18); CERAD, Consortium to Establish a Registry for Alzheimer's Disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2019 15, 8-16DOI: (10.1016/j.jalz.2018.07.215) Copyright © 2018 Terms and Conditions

Fig. 3 Regional distribution and density of neurofibrillary tangles (NFT) throughout the brain in PART (N = 42 subjects). In primary age-related tauopathy (PART), tau lesions in the form of NFTs show a distribution largely limited to the parahippocampal gyrus (entorhinal cortex, transentorhinal cortex, and medial occipitotemporal or fusiform gyrus), hippocampus, amygdala and basal forebrain, with less severe extension to the brainstem and other neocortical regions. The semiquantitative density [16] of NFT is color-coded and is most severe in medial temporal lobe structures. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2019 15, 8-16DOI: (10.1016/j.jalz.2018.07.215) Copyright © 2018 Terms and Conditions

Fig. 4 Comparison of longitudinal rates of change of cognitive performance in 5 domains. Longitudinal rates of cognitive performance change examined in 5 domains (Memory, Attention, Executive Function, Language, and Visuospatial Ability) and Mini-Mental State Examination (MMSE) were found to show a highly significant difference between subjects with primary age-related tauopathy (PART) and Alzheimer's disease (AD) pathology in memory, language, visuospatial ability, and MMSE raw score (prorated for visual impairment) (P = .0034, P = .0019, P = .0051, and P = .016, respectively). In all these domains, AD subjects showed a faster rate of decline than PART subjects. No difference in longitudinal rates of cognitive performance was seen in attention and executive function domains (P = .33, P = .32, respectively). Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2019 15, 8-16DOI: (10.1016/j.jalz.2018.07.215) Copyright © 2018 Terms and Conditions